The <i>Rb1</i>^<i>G</i> mutation does not modify cancer susceptibility of Kras^G12D expressing mice.

(A) Gross morphology of tissue growths that are evident in the mouths and stomachs of tamoxifen treated UBC-Cre-ERT2; KrasG12D mice (top left and right respectively). (B) Morphology of growths in UBC-Cre-ERT2; Rb1G/G; KrasG12D mice (top left and right). Hematoxylin and Eosin staining (lower panels of A and B) show squamous papillomas found in the mouths and stomachs of control KrasG12D and Rb1G/G; KrasG12D animals. Scale bars represent 400μm for low power histology (left) and 100μm for high power (right). (C) Kaplan-Meier analysis of survival of the indicated genotypes. Mice were monitored until natural endpoint. Rb1G/G; KrasG12D (56.5 days post injection) (n = 6) and KrasG12D mice (65 days post injection) (n = 4) are not statistically different from one another using the log rank test (p = 0.475).